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Abstract 
 Orexins are hypothalamic neuropeptides that have a documented role in 
mediating the acute stress response.  However, their role in habituation to repeated 
stress, and the role of orexin receptors (OX1R and OX2R) in the stress response, has 
yet to be defined.  Orexin neuronal activation and levels in the cerebrospinal fluid were 
found to be stimulated with acute restraint, but were significantly reduced by day five of 
repeated restraint.  As certain disease states such as panic disorder are associated with 
increased central orexin levels and failure to habituate to repeated stress, the effect of 
activating orexin signaling via Designer Receptors Exclusively Activated by Designer 
Drugs (DREADDs) on the hypothalamic-pituitary-adrenal (HPA) response was 
evaluated after repeated restraint.  While vehicle-treated rats displayed habituation of 
Adrenocorticotropic Hormone (ACTH) from day 1 to day 5 of restraint, stimulating 
orexins did not further increase ACTH beyond vehicle levels for either acute or repeated 
restraint.  We delineated the roles of orexin receptors in acute and repeated stress by 
using a selective OX2R antagonist (MK-1064).  Pretreatment with MK-1064 reduced day 
1 ACTH levels, but did not allow further habituation on day 5 compared with vehicle-
treated rats, indicating that endogenous OX2R activity plays a role in acute stress, but 
not in habituation to repeated stress.  However, in restrained rats with further stimulated 
orexins by DREADDs, MK-1064 decreased ACTH levels on day 5.  Collectively, these 
results indicate that the OX2R plays a role in acute stress, and can prevent habituation 
to repeated stress under conditions of high orexin release. 
 
Key words: MK-1064, orexin receptor, Hypocretin, Stress, Habituation, DREADDs 
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 Orexins (also called hypocretins) are peptides generated from the prepro-orexin 
precursor that is exclusively localized in cells of the lateral and posterior hypothalamic 
region (de Lecea et al., 1998; Sakurai et al., 1998).  Prepro-orexin is cleaved into two 
highly structurally related and highly conserved peptides, orexin A and orexin B, which 
bind to two G-protein coupled orexin receptors, orexin 1 and orexin 2 receptors (OX1R 
and OX2R, respectively) (de Lecea et al., 1998; Sakurai et al., 1998).  Orexin A has 
nearly equal affinities for both receptors, while Orexin B has higher affinity for OX2R 
(Gotter et al., 2012b).  While many brain regions express both receptors, some regions 
exhibit differential expression (Marcus et al., 2001).  For example, the cingulate cortex 
and locus coeruleus selectively express OX1R, while the paraventricular nuclei of the 
hypothalamus (PVN) and shell neurons of nucleus accumbens preferentially express 
OX2R (Marcus et al., 2001; Trivedi et al., 1998). 
 Orexins are implicated in a wide variety of neuroendocrine and behavioral 
responses including arousal, food intake, cognitive function, autonomic responses, 
emotional memory, and the stress response (Sakurai, 2014).  The most salient 
phenotype of orexin knockouts is reduced arousal resulting in narcolepsy-like behavior, 
which has led to the identification and development of OXR antagonists for the 
pharmacological treatment of insomnia (Gotter et al., 2012a).  Conversely, i.c.v.  
administration of exogenous orexin A to rats or orexin receptor agonists to mice 
promote arousal and wakefulness (Hagan et al., 1999; Nagahara et al., 2015).  Orexins 
are also important in regulating the neurobiological systems that respond to stressful 
stimuli.  For example, orexins promote the hypothalamic-pituitary-adrenal (HPA) axis 
response (Winsky-Sommerer et al., 2004, 2005; Berridge et al., 2010; Johnson et al., 
2012).  Specifically, central orexin administration (either Orexin A or Orexin B) increases 
HPA hormones (Jászberényi et al., 2000; Kuru et al., 2000; Spinazzi et al., 2006).  
Conversely, orexin neurons are activated by corticotropin releasing hormone and 
respond to stressors such as forced swim stress (Winsky-Sommerer et al., 2005; Chang 
et al., 2007; Furlong et al., 2009; Chen et al., 2013).  Both orexin 1 and 2 receptors 
have been implicated in acute stress; the role of each receptor appears dependent on 
the paradigm of stress used (Chang et al., 2007; Gozzi et al., 2013; Bonaventure et al., 
2015).   
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 While this evidence indicates a role for orexins in activating the HPA activity 
under conditions of acute stress, the role of orexin signaling in response to repeated 
stress is not known.  With repeated exposure to moderately intense stressors, 
individuals typically habituate to that stress as indicated by decreasing responsivity in 
behavioral, HPA and autonomic measures (Grissom et al., 2008; Grissom and 
Bhatnagar, 2009).  Failure to habituate to a stressor is a hallmark of stress-related 
illnesses such as post-traumatic stress disorder (PTSD) and panic disorder (Johnson et 
al., 2012).  Moreover, patients with panic anxiety symptoms have higher levels of orexin 
in their cerebrospinal fluid (CSF) (Johnson et al., 2010).  If involved in habituation to a 
stressor, orexins may be a good target for treatment for some of these stress-related 
psychiatric illnesses.   
 To determine the role of orexins in acute and repeated restraint, we first 
characterized orexin neuronal activation and levels in the CSF in both conditions.  We 
found these measures to be increased with acute restraint, but they significantly 
decreased with repeated restraint.  In order to increase orexin activation prior to each of 
five daily 30-min restraints (to model higher orexin levels as observed in panic disorder), 
we used Designers Receptors Exclusively Activated by Designer Drugs (DREADDs) 
driven by the orexin promoter.  We found that even with additional orexin stimulation, 
HPA activation habituated by day 5 of restraint.  However, we were able to delineate the 
roles of orexin receptors in acute and repeated stress using a selective OX2R specific 
antagonist (MK-1064) (Roecker et al., 2014).  Prior to this, the roles of orexin receptors 
in the stress response, whether acute or repeated, had not yet been fully characterized.  
As OX2R is abundant in the PVN and is known to play a role in arousal, it may mediate 
excitatory effects at this site where the HPA response is initiated (Shirasaka et al., 2001; 
Gotter et al., 2012b).  In support of this, we found that OX2R receptor promotes the 
acute stress response, and it partially prevents habituation to repeated stress only in 
conditions of high orexin release. 
 
 
 5 
EXPERIMENTAL PROCEDURES 
Animals 
 Adult male Sprague Dawley rats (225-250g) were obtained from Charles River 
Laboratories (Wilmington, MA, USA).  Rats were singly housed in polycarbonate 
enclosures with standard bedding and with food and water available ad libitum.  Animals 
were acclimated to a 12-h light-dark cycle with lights on at 06:15 and lights off at 18:15 
in a temperature controlled vivarium for at least 5 days prior to administration of any 
stress protocols.  All experiments took place during the inactive phase between 0800-
1200 (Zeitgeber Time 01:45-05:45).  Experiments followed the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the Children’s Hospital of 
Philadelphia Research Institute’s Animal Care and Use Committee.   
 
Stereotaxic delivery of DREADDS-containing viruses 
 Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are 
constructs packaged into viruses that contain synthetic G protein coupled receptors 
(GPCRs) and can be activated by the otherwise pharmacologically inert ligand 
Clozapine-N-Oxide (CNO).  We obtained the CMV-hM3Dq-mCitrine plasmid from Dr.  
Bryan Roth (University of North Carolina, Chapel Hill, NC).  Slice electrophysiology has 
demonstrated that CNO application to cells expressing this Gq coupled designer 
receptor causes depolarization and increases firing rate (Alexander et al., 2009).  We 
next obtained a 1295 bp promoter for human preproorexin gene (Ple112) from Addgene 
plasmid No.  29004 (gift of Dr.  Elizabeth Simpson, Univ.  of British Columbia).  This 
promoter was subcloned upstream of the hM3Dq-mCitrine region to replace the 
construct's CMV promoter to drive transgene expression specifically in orexin neurons.  
The fragment Ple112-hm3Dq-mCitrine was then subcloned between the Inverted 
Terminal Repeats (ITRs) of the AAV2 genome.  In a separate study, we found AAV1 
serotype displayed optimal tropism for Sprague Dawley rat hypothalamic neurons when 
we delivered in vivo and compared to AAV5,8,9 expression of GFP reporters driven by 
common constitutively active promoters Synapsin and CB7.  Based on this finding, The 
University of Pennsylvania Vector Core produced a recombinant adenovirus rAAV2/1-
Ple112-hM3Dq-mCitrine (using AAV1 serotype capsid for optimal transduction in orexin 
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neurons) for our use.    
 Surgeries were performed in aseptic conditions.  Animals were anesthetized 
using a cocktail of ketamine, xylazine, and acepromazine.  Using stereotaxic technique, 
DREADDs-containing virus (109 titer, 1ul bilaterally) was injected into the lateral 
hypothalamus (coordinates: 2.5 mm caudal to bregma, 1.8 mm from mid-line and 8 mm 
ventral to dura mater).  After surgery, animals were injected with meloxicam (2mg/kg).  
Animals recovered for 4 weeks while virus expressed before any further experiments 
were performed.   
 Immunofluorescence staining for visualizing the virus tag was conducted as 
follows.  Rats were rapidly decapitated and brains were flash frozen in 2-methyl butane.  
Coronal sections for the lateral hypothalamus were cut on a cryostat into six serial sets 
of 20-um-thick sections directly onto the slide.  Rostral-caudal coordinates (relative to 
bregma) for the lateral hypothalamic area analyzed were -2.12 mm to -3.60 mm.  Tissue 
was fixed for 30 minutes in 4% paraformaldehyde (Electron Microscopy Sciences; 
Hatfield, PA).  Sections were washed several times with Phosphate Buffered Saline 
(PBS; pH 7.4) with 0.3% Triton-X (Sigma-Aldrich; St Louis, MO), and then incubated 
with primary antibodies for both Orexin A (1:250, sc-8070; Santa Cruz Biotechnology, 
Santa Cruz CA) and GFP (1:500, ab290; AbCam, Cambridge, UK) in a solution of PBS 
with 5% Normal Donkey Serum (EMD Millipore; Billerica, MA) and 0.3% Triton-X 
overnight.  As the mCitrine tag on the DREADDs-containing virus originates from 
Aquorea victoria jellyfish, GFP antibodies are known to react with these proteins (Le et 
al., 2006).  Sections were rinsed several times in PBS, followed by the addition of 
AlexaFluor488 Donkey anti-goat and AlexaFluor647 Donkey anti-rabbit (1:200, A-11055 
and A-31573; Life Technologies, Carlsbad, CA).  Sections were given a final set of 
washes and coverslipped with fluoromount.  Images were acquired with a Leitz DMR 
microscope with a digital camera (Leica Microsystems; Buffalo Grove, IL).  The NIH 
Image J colocalization plugin was used to determine percent orexin cells transduced by 
the virus. Quantification revealed 71 + 5.4% of neurons within the lateral hypothalamus 
exhibited the DREADDs tag. Roughly 1% of these cells were not dual labeled with 
orexin A antibody.  
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Drugs 
 Clozapine N-Oxide (CNO; Sigma-Aldrich; St Louis, MO) was dissolved in saline 
and 8% DMSO and injected intraperitoneally at 2 mg/kg in a 5 mg/mL solution.  This 
dose is in accordance with doses used in previous DREADDs studies in rats (Farrell 
and Roth, 2013).  MK-1064, a selective OX2R antagonist, ( Roecker et al., 2014) was 
dissolved overnight in 20% Vitamin E d-a-tocopherol polyethylene glycol 1000 succinate 
(Vit E-TPGS) (Sigma-Aldrich; St Louis, MO).  Rats were orally administered either 20% 
Vit E-TPGS as vehicle or 30 mg/kg MK-1064, both at 1mL/kg for consistent volume.  All 
animals were given a vehicle dose 1 day prior to the start of the restraint paradigm to 
habituate to the oral gavage procedure.  Animals received injections of vehicle (20% Vit 
E TPGS, p.o.) or MK-1064 and vehicle (saline and 8% DMSO, i.p.) or CNO 90 minutes 
prior to the start of the 30-minute restraint.  This timing was chosen based on the fact 
that both MK-1064 and CNO have been shown to promote behavioral effects in the rat 
within 30 minutes of administration and effects last up to 4 hours after administration 
(Alexander et al., 2009; Farrell and Roth, 2013; Hasegawa et al., 2014; Roecker et al., 
2014).  Additionally, CNO was given at the time of MK-1064 injection to minimize the 
effects of repeated handling prior to restraint. 
 
Assaying orexin levels in the cerebrospinal fluid (CSF) 
 DREADDs-expressing rats were injected IP with either vehicle or CNO 90 
minutes prior to either CSF collection. In a separate experiment, DREADDs-expressing 
rats were injected IP with vehicle or CNO 90 minutes prior to stress exposure. 
Specifically, rats were either exposed to 1 or 5 days of 30-min restraint (IP injections 
were given daily prior to each restraint for the 5-day group). Animals were restrained in 
Plexiglas restrainers (9 x 3.5 inches) made from the University of Pennsylvania Machine 
Shop.  Plexiglas inserts (7.5 x 3.25 inches) were placed inside the restrainers 
appropriate for the size of each male rat so that they could not turn around in the 
restrainer.  As orexins are known to exhibit a circadian rhythm (Taheri et al., 1999; Fujiki 
et al., 2001; Zeitzer, 2013), animals were restrained within 2 hours after lights on, a time 
at which orexin levels reach a nadir.  At 15 min into the 1st or 5th restraint, CSF was 
collected (rough 105 minutes post IP injection). Briefly, rats were anesthetized with a 
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cocktail of ketamine and xylazine, placed in the ear bars of a stereotaxic apparatus with 
their nose pointing downward, and a 25-gauge needle was used to extract 100 uL of 
CSF from the cisterna magna. CSF was ejected into eppendorf tubes and frozen at -
80°C until radioimmunoassay.  CSF levels of orexin were assayed with a 
Radioimmunoassay kit from Phoenix Pharmaceuticals (Burlingame, CA).  The minimum 
levels of detection for orexin was 80 pg/ml.  Intra-and interassay variability was 5-7% 
and 12-15%, respectively. 
  
Assaying orexin neuronal activation  
 Two additional groups of rats were injected with the DREADDs construct and 
exposed to either 1 or 5 days of restraint with injections of vehicle or CNO administered 
as previously described.  Brains were collected for one group of rats on Day 1 of 
restraint (30 min after restraint ended), while brains were not collected in the other 
cohort until Day 5 of restraint.  The lateral hypothalamus of these brains were further 
analyzed for orexin neural activation.  Specifically, sections of the lateral hypothalamus 
were cut and fixed as described above in DREADDs immunofluorescent staining.  
Sections were incubated with c-Fos antibody (1:1250, sc-52; Santa Cruz Biotechnology, 
Santa Cruz, CA) followed by Biotin-SP-conjugated AffiniPure Donkey-Antirabbit IgG 
(1:200, Jackson Immunoresearch), which was visualized with a 3’3’-diaminobenzidine 
reaction (Sigma-Aldrich, St Louis, MO).  Sections were then stained for orexin A (1:50, 
sc-8070; Santa Cruz Biotechnology, Santa Cruz CA) followed by biotinylated Horse 
Anti-Goat antibody (1:500, BA-9500; Vector Laboratories, Burlingame, CA.), which was 
visualized with a Nova Red reaction (SK-4800, Vector Laboratories, Burlingame, CA).  
Sections were mounted with permount (Electron Microscopy Sciences, Fort 
Washington, PA).  Images were acquired with a Leitz DMR microscope with a digital 
camera (Leica Microsystems; Buffalo Grove, IL).  4 sections per animal (with rostral-
caudal coordinates (relative to bregma) ranging from -2.04 to -3.24) were analyzed 
using NIH Image J. Specifically, a standardized box encompassed the lateral 
hypothalamus (calculated using Paxinos & Watson Rat Brain Atlas) and dual labeled 
cells were counted by hand.  All image analysis was performed with the experimenter 
blind to the treatment groups. 
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Assessing HPA reactivity to acute or repeated restraint with orexin manipulations 
 A naïve cohort of rats injected with DREADDs-containing virus was exposed to 
either 1 or 5 consecutive days of restraint with injections of vehicle or CNO IP and either 
vehicle or MK-1064 administered PO 90 min prior to each restraint.  See Fig. 3A for 
depiction of experimental paradigm.  Animals were weighed on Day 1 and Day 5 of 
restraint.  Video cameras were set up above the restrainers in order to record struggle 
behavior on day 2 of restraint.  While rats are in the restrainer for 30 minutes, most of 
the struggle behavior occurs within the first 10 minutes.  Therefore, we analyzed 
struggle behavior during this time period.  A trained investigator blind to experimental 
groups hand scored struggle behavior – defined as attempts to escape, or intense 
movement of the animal while in the restrainer.  Blood was collected on Day 1 and Day 
5 of restraint to assess the HPA response to acute and repeated restraint, respectively.  
Briefly, on day 1, tail blood was taken at 0 minutes (prior to being placed in restraint), 
again at 15 minutes and 30 minutes (during restraint), and at 60 minutes (recovery time 
point in the home cage).  Plasma corticosterone and ACTH were assayed with a 
Radioimmunoassay kit from MP Biomedical (Orangeburg, NY).  The minimum levels of 
detection for ACTH and corticosterone were 5.7pg/ml and 0.6μg/dl, respectively.  Intra-
and interassay variability was less than 10%.   
 
Statistical Analysis 
 Data are presented as the mean ± the standard error of the mean. For 
habituation of vehicle-treated animals, a 2-way ANOVA assessed Day and Time 
variables (Day 1 and 5 were compared, as well as the time point throughout restraint). A 
t-test was used to evaluate orexin neural activation and orexin levels in the CSF in 
control versus CNO treated animals on Day 1 and Day 5 of restraint.  A 2-way ANOVA 
assessed Day and Drug variables for orexin neural activation and orexin A in the CSF 
throughout repeated restraint. For struggle behavior and body weight, a 2-way ANOVA 
assessed CNO and 2-SORA variables.  For all other ACTH data, a 2-way ANOVA 
assessed Drug and Time variables on Day 1 and Day 5 separately. When warranted, 
Tukey’s-corrected t-tests were performed.  All hypothesis tests used =0.05 as the 
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criterion level of significance.  Statistical analysis was conducted with GraphPad Prism 
(GraphPad Software, La Jolla, CA, USA) in order to identify statistical differences.   
 
RESULTS 
Orexin levels habituate with repeated stress 
Habituation of the HPA response to 5 days of restraint stress was assessed by 
evaluating plasma ACTH levels prior to, during and after 30 minutes of restraint stress 
on day 1 and day 5 of restraint (paradigm and data in Fig. 1A).  Consistent with 
previous results (Grissom and Bhatnagar, 2009), male rats in this paradigm habituated 
to 5 days of repeated restraint with regard to plasma ACTH levels.  This effect was 
significant at 30 minutes of restraint.  However, we did not observe habituation or group 
differences in our corticosterone assays, consistent with previous lab results that it 
takes 8-10 days of restraint to see corticosterone effects ((Grissom et al., 2008); data 
not shown). 
 After demonstrating ACTH habituation to repeated restraint, we examined 
changes in orexins from one day to five days of daily 30-min restraint.  To assess this, 
orexin neuronal activation and CSF levels of orexin were evaluated on both day 1 and 
day 5 of restraint.  Representative images of the cFos/orexin dual stain on day 1 and 
day 5 of restraint are displayed in Fig. 1B.  An average of 40 orexin cells per section 
were dual labeled with cFos after a single 30-min restraint, and this was significantly 
reduced to nearly half that amount by day 5 of restraint stress. In terms of percentages 
of total orexin neurons present, a single 30-min restraint activated 75% of orexin 
neurons, whereas only 40% were active on day 5 of restraint stress (data not shown).  
Orexin A levels in CSF showed a similar pattern to orexin neuronal activation, since 
orexin A levels in CSF habituated after 5 days of restraint stress (Fig. 1C).  Specifically, 
orexin A levels were significantly reduced to approximately 66% of the day 1 value.  In 
summary, both HPA and orexin activity decreased with repeated restraint stress. 
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Stimulation of orexins prior to each of five daily 30-min restraints 
As certain disease states such as panic disorder are associated with increased central 
orexin levels and failure to habituate to repeated stress, we further stimulated orexins 
prior to each of five daily 30-min restraints.  To do this, DREADDs were injected and 
expressed selectively in orexin neurons to activate these neurons.  Representative 
fluorescent images of DREADDs expression at four weeks are displayed in Fig. 2A, 
along with a depiction of the spread of viral expression along four levels of Bregma 
(anterior to posterior) in Fig. 2B.  Quantification revealed 71 + 5.4% of neurons within 
the lateral hypothalamus exhibited the DREADDs tag (data not shown). Orexin levels in 
the CSF are quantified for vehicle- or CNO-treated DREADDs-expressing rats in non-
stress conditions in Fig. 2C.  Relative to vehicle, CNO significantly increased the level 
of orexins in the CSF compared with vehicle-treated rats when evaluated 90 minutes 
after treatment.  These data validated the functionality of the DREADDs construct. 
Moreover, orexin neuronal activation with DREADDs stimulation prior to each of 
five daily 30-min restraints were quantified (Fig 2D).  Compared with vehicle treatment, 
CNO significantly increased the number of orexin neurons dual labeled with cFos (and 
hence neural activation) on day 1 of restraint. The level of CNO-induced orexin neuron 
recruitment on day 5, however, remained significantly below that seen on day 1 of 
restraint stress after CNO (just as was seen with vehicle-treated groups on day 1 
compared with day 5). 
Lastly, orexin levels in the CSF with DREADDs stimulation prior to each of five 
daily 30-min restraints were quantified (Fig 2E). Relative to vehicle-treated animals, 
CNO induced orexin A in CSF to significantly greater levels on day 1, verifying that 
DREADDs-mediated CNO activation of orexin neurons resulted in augmented release 
of orexin A neuropeptide. While CNO treatment also increased orexin A levels on day 5 
of restraint compared with vehicle treatment, CNO-treated animals exhibited 
significantly reduced orexin A levels on day 5 compared with day 1 of restraint, just as it 
did in vehicle-treated animals.  Together, these data indicate that the DREADDs 
constructs increased orexin activation and levels in the CSF, but repeated restraint 
stress partially counteracts these effects by lowering orexin activity and levels in the 
CSF compared to day 1 of restraint. 
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OX2R underlies struggle behavior and body weight change during restraint stress 
 The contribution of orexin receptor signaling in both struggle behavior and body 
weight change in response to restraint stress was determined through use of a selective 
OX2R antagonist, MK-1064.  Specifically, after DREADDs expression, rats underwent 5 
consecutive days of 30-minute restraint, with either vehicle or CNO to stimulate 
DREADDs prior to each restraint, and with either vehicle or MK-1064 to antagonize the 
orexin 2 receptor (paradigm depicted in Fig. 3A).  Struggle behavior indicates the 
number of attempts to escape during restraint, which is an important component of the 
stress response and habituates with repeated restraint (Grissom et al., 2008).  As 
demonstrated in Fig. 3B, the CNO/vehicle group spent significantly more time struggling 
than the other three treatment groups.  Essentially, stimulating orexins with CNO 
increases struggle behavior, and blocking OX2R with MK-1064 reverses this effect.  
Coincident with changes observed in struggle behavior, body weight decreased from 
the first to last day of restraint in levels of high orexin, but this was eliminated with MK-
1064 pretreatment (Fig. 3C).  Thus, while all rats lost weight over the 5 days of restraint 
stress, further stimulating orexins prior to each 30-min restraint exacerbated this effect 
and these results appear mediated through OX2R. 
 
OX2R is involved in the ACTH response to acute restraint stress 
 The role of orexin signaling in the HPA response to acute restraint stress was 
determined by measuring plasma ACTH levels in response to 30 minutes of restraint in 
DREADDs-expressing rats pretreated with either vehicle or CNO in combination with 
either vehicle or the OX2R antagonist, MK-1064.  CNO pretreatment did not increase 
ACTH levels compared with that from vehicle-treated rats (Fig. 4A). Pretreatment with 
MK-1064, however, significantly attenuated the ACTH response in combination with 
either vehicle (Fig. 4B), or CNO pre-treatment (Fig. 4C), indicating that OX2R is 
responsible for mediating at least part of the ACTH response to acute restraint.  
Importantly, the ACTH response was similarly attenuated by MK-1064 in either the 
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presence or absence of CNO (Fig. 4D), indicating that activation of orexin signaling 
through mechanisms not involving OX2R contributes little to the ACTH response on this 
first day of restraint stress. 
 
Orexin signaling through OX2R and non-OX2R mechanisms have opposing 
influences on ACTH responses to repeated restraint stress   
 The role of orexin signaling in mediating the HPA response to repeated stress 
was evaluated in Fig. 5.  Specifically, rats were evaluated for plasma ACTH levels on 
the 5th day of restraint stress following treatment with CNO and/or MK-1064.  CNO 
treatment did not change ACTH levels on day 5 of restraint compared with vehicle-only 
controls (Fig. 5A).  In the absence of CNO, blockade of endogenous OX2R activity by 
MK-1064 also did not further affect plasma levels of ACTH compared with vehicle (Fig. 
5B), unlike that seen on the first day of restraint stress.  However, in rats treated with 
CNO to induce orexin neuron activation in combination with MK-1064, the ACTH 
response was attenuated further (Fig. 5C).  Because ACTH levels are elevated 
following stimulation of orexin neuron activation (CNO/Vehicle) relative to that following 
stimulation of orexin neuron activation plus antagonism of the OX2R (CNO/MK-1064), 
these results indicate that OX2R activity has the capacity to increase ACTH levels after 
5 days of restraint stress.  In other words, exogenous OX2R activity prevents the full 
habituation to repeated restraint.  Indeed, ACTH responses are reduced by the 
CNO/MK-1064 manipulation relative to the Vehicle/MK-1064 treatment (Fig. 5D). This 
comparison evaluates the influence of total orexin neuron activity minus that of OX2R,  
indicating that possibly OX1R, or other mechanisms induced by orexin neuron activity, 
has the capacity to further reduce ACTH responses to repeated restraint stress.   
 
DISCUSSION 
 While orexins are known to play a role in the acute stress response, it was 
unclear how they mediated the response to repeated stressors, and the contribution of 
orexin receptors to both acute and repeated stress was undetermined.  With repeated 
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exposure to modest stressors, individuals typically habituate to that stress by 
decreasing responsivity, particularly in HPA measures (Grissom et al., 2008; Grissom 
and Bhatnagar, 2009).  Failure to habituate is a hallmark of stress-related illnesses such 
as post-traumatic stress disorder (PTSD) and panic disorder (Johnson et al., 2012).  
The present studies demonstrated HPA habituation to repeated restraint in male 
rodents, and determined that both orexin neuronal activation and levels in the CSF 
decrease after repeated restraint.  As central orexins are augmented in some disease 
states such as panic disorder (where patients fail to habituate to repeated stress), high 
levels of orexin were stimulated via DREADDs prior to each of five daily 30-min 
restraints.  Our data confirm that our DREADDs construct was efficacious in stimulating 
orexin neuronal activation and increasing orexin levels in the CSF in non-stress 
conditions, as well as in acute and repeated restraint.  We were also able to discern the 
contribution of orexin receptor signaling in acute and repeated stress through use of a 
selective OX2R antagonist, MK-1064.  We found that the OX2R contributed to struggle 
behavior and body weight decrease during repeated restraint.  Moreover, the OX2R 
played a role in the plasma ACTH response to acute stress and repeated stress, 
although the latter was only in conditions of high orexin release.   
 Orexins and the HPA axis reciprocally interact.  Specifically, central orexin 
increases corticosterone and ACTH, whereas CRH depolarizes orexin neurons (Russell 
et al., 2001; Samson et al., 2002; Winsky-Sommerer et al., 2004).  The activation of 
orexin neurons during acute stress has been examined by a limited number of studies 
using a wide variety of stress paradigms (Chang et al., 2007; Furlong et al., 2009; Chen 
et al., 2013).  As much of the previous literature has focused on the role of orexin A in 
stress (Ida et al., 2000; Russell et al., 2001; Sakamoto et al., 2004), our studies 
specifically examined orexin A activity both through dual labeling of orexin A neurons 
with cFos (a measure of neural activation) and orexin A levels in the CSF in acute and 
repeated stress.  Importantly, our results indicate that acute restraint stress induces 
very high levels of orexin neuron activation (75%), accompanied by increased levels of 
orexin A in the CSF.  We also show, for the first time, that orexin activity decreases with 
habituation to repeated stress.  Thus, with repeated exposure to a moderately intense 
stressor, both the HPA and orexin response diminish.  When inducing additional orexin 
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activation via DREADDs prior to each of five daily 30-min restraints, we were unable to 
increase orexin neuron activation to the levels seen with acute stress. Based on the 
literature, CNO does not appear to become less effective after repeated administration, 
so this is likely not the cause for these results (Kozorovitskiy et al., 2012). Moreover, 
this reduced responsiveness of orexin neurons does not appear due to depletion of 
available orexin neuropeptide stores, since DREADDs-induced CSF levels of orexin A 
and orexin neuron activation as measured by c-fos expression were both attenuated 
during habituation. It is important to note that Orexin B also plays an important role in 
the stress response (Kuru et al., 2000; Shirasaka et al., 2001; Spinazzi et al., 2006), so 
assessing orexin B levels in the future may shed more light on how the orexins are 
involved in repeated stress. 
Struggle behavior and body weight changes are important components of the 
response to stressful stimuli.  Our data show that exogenous orexin stimulation 
increased struggle behavior and decreased body weight.  This was reversed by the 
OX2R antagonist, indicating that OX2R plays a role in these components of the stress 
response in conditions of high orexin release.  This effect on struggle behavior is 
consistent with literature support for the OX2R in promoting arousal (Gotter et al., 
2012b). Moreover, arousal is an important component of the stress response (Giardino 
and de Lecea, 2014), so it is likely that DREADDs-induced orexin activation is 
increasing struggle behavior by increasing arousal. However, our data indicate that 
DREADDs differentially modulate the HPA response and struggling behavior, thus, 
mechanisms above and beyond those regulated by orexins may be involved. Although 
orexin antagonists are known to promote sleep (Gotter et al., 2016), they still allow 
arousability to salient stimuli (Tannenbaum et al., 2014, 2016). Thus, it is unlikely that 
reduction in struggle behavior is due to the sedative effects of the OX2R antagonist. 
However, as we did not directly measure sleep using telemetry devices, this possibility 
cannot be ruled out. 
It is unclear where OX2Rs are acting to regulate struggle behavior and body 
weight gain.  Previous literature has indicated that rats with high amygdala excitability 
show increased struggling behavior (Anisman et al., 1997; McIntyre et al., 1999).  Given 
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that OX2Rs are expressed in medial but not central amygdala, this subnuclei of the 
amygdala could be an important substrate for regulating struggle behavior (Marcus et 
al., 2001).  Alternatively, both central and peripheral regions may play a role in OX2R 
mediation of body weight gain.  For example, central orexins acting on hypothalamic 
and dopaminergic brain regions have been implicated in increasing spontaneous 
physical activity and nonexercise thermogenesis (Kotz et al., 2012).  Moreover, orexins 
acting on white adipose tissue have been shown to promote lipolysis (Perez-Leighton et 
al., 2014).  Thus, it is possible that the reduction in body weight observed with CNO 
treatment is a result of increased energy expenditure and lipolysis by animals in this 
treatment group. 
 There have been few studies delineating the contribution of each orexin receptor 
to the acute HPA response.  One study reports that pretreatment with an OX2R 
antagonist prevents forced swim-induced increases in plasma ACTH and corticosterone 
(Chang et al., 2007).  This is consistent with our findings that OX2R contributes to the 
HPA response induced by acute restraint stress.  However, as MK-1064 pretreatment 
only reduced the HPA response by half, it is still possible that the other components of 
the stress response may play a role in regulating the acute HPA response to restraint.  
Possible components would not include the contribution of OX1R, however, as the 
ACTH response was similarly attenuated by MK-1064 in either the presence or absence 
of CNO.  As OX2R is preferentially expressed (over OX1R) in the paraventricular 
nucleus of the hypothalamus, antagonizing OX2R (but not necessarily OX1R) would 
likely reduce the acute HPA response (Shirasaka et al., 2001; Gotter et al., 2012b).  
However, other sites expressing OX2R such as the amygdala, paraventricular nucleus 
of the thalamus (PVT), and hippocampus may also be involved (Marcus et al., 2001). 
 We found that under endogenous orexin levels elicited by restraint alone, 
blocking OX2R had no effect on ACTH levels on day 5 of restraint.  Thus, in these 
conditions, OX2R does not affect habituation.  However, our data measuring orexin 
levels in the CSF revealed that compared with one day of 30-min restraint, orexin levels 
decreased by five days of daily 30-min restraint.  Hence, blocking OX2R in low orexin 
conditions may not have an effect.  However, when orexins are stimulated with 
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DREADDs, blocking OX2R further attenuates ACTH responses. This indicates OX2R 
plays a role in repeated restraint stress only in conditions of high orexin release.  This 
also indicates that OX2R desensitization does not appear to be involved in typical 
habituation. However, the ultimate effects of orexins throughout stress might be 
dependent on the balance of signaling from both orexin receptors (Scott et al., 2011). 
Though, not much is known about orexin receptor regulation after stress. While the 
OX2R activity promotes ACTH release and prevents habituation in high levels of orexin 
such as that seen during acute stress conditions, one possibility is that OX1R activated 
by orexin release could promote habituation, as CNO/MK-1064 treated animals have 
even lower plasma ACTH levels than Vehicle/MK-1064 treated animals after repeated 
restraint. Thus, one interpretation of the results is that OX1R underlies habituation. 
Direct tests of OX1R function are required to confirm this interpretation.  Interestingly, 
previous data from our lab indicates that the OX1R in the posterior paraventricular 
thalamus is necessary in adapting to repeated swim stress, allowing facilitation to a 
novel restraint stressor (Heydendael et al., 2011). However, it is not clear whether 
orexins are involved in facilitation after habituating to repeated restraint.  Overall, we 
believe the evidence suggests that orexin neuron has the capacity to influence 
habituation through opposing OX2R and non- OX2R mechanisms. 
 The results from this study improve our understanding of the role of orexin 
receptors in regulating the HPA response to both acute and repeated stress.  We have 
confirmed the involvement of OX2R in acute stress, and have shown that it has the 
capacity to promote ACTH levels opposing habituation to repeated stress in conditions 
of exogenously elevated orexin signaling. Future studies should identify not only the 
neuronal pathways regulating the reduced responsiveness of orexin neurons during 
habituation, but also investigate the specific brain regions where each receptor may be 
acting to influence these changes in HPA activity, struggle behavior, and body weight 
gain.  While there are high concentrations of OX2R in the PVN, the locus coeruleus 
preferentially expresses OX1R (Peyron et al., 1998; Marcus et al., 2001).  Additionally, 
other stress regulatory regions with high concentrations of orexin input include the PVT 
and the amygdala.  These experiments would allow for a greater understanding of 
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mechanisms associated with hyperactivation of orexin signaling observed in psychiatric 
illness such as panic disorder. 
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Figure Legends 
Fig. 1. Orexin levels habituate with repeated restraint stress (n = 10/group).  (A) Left: 
Depiction of Restraint Paradigm and Blood collection. Right: Plasma ACTH data for Day 
1 and Day 5 of restraint. Vehicle/Vehicle-treated animals display habituation over the 5 
days of restraint stress, with decreased plasma ACTH values on day 5 compared to day 
1 (2-Way ANOVA, Day: F(1, 67) = 8.2, p = 0.006; Time: F(1,67) = 12.7, p<0.0001).  (B) 
Total orexin neurons dual labeled with cFos on day 1 versus day 5 of restraint stress (T 
test, p<0.05).  Right, representative 10x magnification images of the lateral 
hypothalamus with cFos (black) and orexin (red) dual stain on Day 1 and 5 of restraint.  
(C) Orexin levels in the CSF on day 1 and 5 of restraint stress (T test, p<0.05).  *p<0.05, 
**p<0.01, ***p<0.0001 
 
Fig. 2.  Stimulation of orexins prior to each of five daily 30-min restraints (n = 10/group).  
(A) Representative images of DREADDs expression in the lateral hypothalamus at 20x 
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magnification.  Orexin Neurons = red, DREADDs tag = green, orexin neurons 
transfected with virus = yellow.  (B) Viral expression along four levels of Bregma 
(anterior to posterior) in a cartoon using rat brain atlas images.  Each red dot represents 
10 cells expressing the viral tag.  (C) Orexin A levels in CSF following vehicle or CNO 
treatment (non-restraint stress conditions; T test, p<0.001).  (D) Total orexin neurons 
dual labeled with cFos in acute and repeated restraint stress following either vehicle or 
CNO pretreatment (2-Way ANOVA, Day: (F(1,62) = 9.6, p<0.001; CNO: F(1,62) = 4.1, 
p<0.05, Interaction: F(1,62) = 0.01, p = 0.95).  (E) Orexin A levels in the CSF following 
acute and repeated restraint stress with either vehicle or CNO pretreatment (2-Way 
ANOVA, Day: (F(1,37) = 26.47, CNO: p <0.0001; Interaction: F(1,37) = 15.05, p = 
0.0004; F(1,37) = 2.6, p = 0.11).  *p<0.05, ***p<0.001  
 
Fig. 3.  OX2R underlies struggle behavior and body weight change during restraint stress 
(n=7/group).  (A) Timeline of experimental procedures.  DREADDs-containing viruses 
were injected into the lateral hypothalamus 4 weeks prior to the start of the restraint 
paradigm.  MK-1064 and CNO were administered orally or subcutaneously, respectively, 
90 minutes prior to each 30-minute restraint for 5 consecutive days.  Tail blood was 
collected at 0, 15, 30, and 60 minutes on day 1 of restraint for hormone assays.  Struggle 
Behavior was quantified on Day 2 of restraint.  Tail blood was collected at 0, 15, and 30 
minutes on day 5 of restraint.  Rats were euthanized at 60 minutes, with both blood and 
brain collected at this time.  (B)  Orexin activation by CNO increases struggle behavior 
(2-Way ANOVA, CNO: (F(1,22) = 9.8, p = 0.005; MK-1064: F(1,22) = 7.4, p = 0.013; 
Interaction: F(1,22) = 4.7, p = 0.042).  (C) Body weight change after 5 days of restraint 
stress in rats differentially treated with CNO and/or MK-1064 (2-Way ANOVA, MK-1064: 
(F(1,23) = 4.3, p = 0.049; Interaction: F(1,23) = 3.1, p = 0.09).  **p<0.01  
 
Fig. 4.  OX2R is involved in the ACTH response to acute restraint stress (n = 12/group).  
ACTH levels were evaluated on the first day of restraint stress following vehicle/vehicle 
versus CNO/vehicle pretreatment to evaluate orexin neuron activation (A; no 
significance by ANOVA), vehicle/vehicle versus vehicle/MK-1064 pretreatment to 
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evaluate the role of endogenous OX2R (B; significant: 2-Way ANOVA, MK-1064: 
(F(1,63) = 9.3, p = 0.003), CNO/MK-1064 versus CNO/vehicle pretreatment to assess 
the effect of exogenous OX2R activity induction (C; significant: 2-Way ANOVA, Drug: 
F(1,71) = 4.6, p = 0.035), or Vehicle/MK-1064 versus CNO/MK-1064 pretreatment to 
understand the role of orexin-induced mechanisms other than OX2R (D; no significance 
by ANOVA). *p<0.05, **p<0.01  
 
Fig. 5.  OX2R and non-OX2R mediated orexin mechanisms have opposing influences on 
ACTH responses to repeated restraint stress.  (n=12/group) ACTH levels were evaluated 
on the fifth day of restraint stress following vehicle/vehicle versus CNO/vehicle 
pretreatment to evaluate orexin neuron activation (A; no significance by ANOVA), 
vehicle/vehicle versus vehicle/MK-1064 pretreatment to evaluate the role of endogenous 
OX2R (B; no significance by ANOVA), CNO/MK-1064 versus CNO/vehicle pretreatment 
to assess the effect of exogenous OX2R activity induction (C; significant: 2-Way ANOVA, 
Drug: F(1,45) = 13.1, p = 0.001), or Vehicle/MK-1064 versus CNO/MK-1064 pretreatment 
to understand the role of orexin-induced mechanisms other than OX2R (D; significant: 2-
Way ANOVA, Drug: F(1,40) = 12.02, p<0.01).  *p<0.05, **p<0.01  
 
 
